astrazeneca

Micromet shares traded some 3.3% higher on Monday after the small-cap biotech announced that its candidate drug blinatumomab led to remission in almost four-fifths of leukemia patients in a Phase II trial. It also said that a Phase I trial showed the drug induced durable remission in patients with non-Hodgkin lymphoma.

Entering February, a mixed picture on employment has developed: Job cuts in January reached their highest total since August, but still represent a 70% reduction from the same time a year ago, when they peaked at 241,749. What's going on?

Company news that could affect stock prices today including: a Swiss court's decision that chief financial markets regulator broke the law when it ordered UBS AG to give the U.S. data about its clients, and Teva Pharmaceutical Industries' withdrawal of its appeal of a U.S. court ruling that favored Merck and its patent on the asthma treatment Singulair.

News that could affect stock prices today: Pfizer and India's Strides Arcolab reached an agreement that will expand the off-patent generic drugs in the U.S. drug maker's portfolio; Kraft's hostile takeover bid for Cadbury received conditional antitrust approval by the European Union.

AstraZeneca scored a win on Tuesday, when a Food and Drug Administration advisory panel recommended broader use of Crestor, the company's cholesterol-lowering drug. The panel recommended that those with low cholesterol use the drug, following studies finding that Crestor reduces the risk of heart disease even in those with normal cholesterol levels.

AstraZeneca (AZN) has had a good week with its anticlotting drug Brilinta (ticagrelor). It impressed many observers by announcing positive results of a late-stage head-to-head study and a mid-stage study for Brilinta, and on Thursday, it said it had filed for Food and Drug Administration approval....

Ever since China loosened its trade restrictions with the West, companies have jumped head-first into the Communist-run state, hoping to capitalize on selling products to the planet's most populous nation. Pharmaceutical companies have been no different, but at a somewhat more subdued rate because...

While the swine flu pandemic remains a downer for public health officials worldwide, the H1N1 virus proved to be an upper for several pharmaceutical companies' third-quarter earnings. GlaxoSmithKline (GSK), AstraZeneca (AZN) and Sanofi-Aventis (SNY), which make vaccines against the virus, posted...

The global pharmaceutical market is set to grow 4 percent to 6 percent next year, exceeding $825 billion, market intelligence and research company IMS Health (RX) said on Oct 7. This is higher than previous IMS estimates by one percentage point. Through 2013, the researcher predicts worldwide...

With kids back in school and winter on its way, swine flu is expected to spread big time. Some forecasts warn the H1N1 virus could potentially infect half the U.S. population by the end of the year. The question is, are we ready? The H1N1 virus first emerged in Mexico earlier this year, setting...